Concerns at BIO 2026: Biotech Leaders Address Chinese Competition and AI Profitability
At BIO 2026, biotech executives expressed worries about the impact of Chinese biotech on the industry, alongside discussions on AI profitability and the sustainability of Trump's drug pricing policies.
Editorial Staff
1 min read
Updated 19 days ago
During the BIO 2026 event, biotech executives gathered to discuss pressing issues affecting the industry, particularly the challenges posed by Chinese biotech.
Concerns were also raised regarding the profitability of artificial intelligence within the sector, highlighting the need for advancements in this area.
Additionally, the durability of former President Trump's drug price policies was a significant topic of conversation, reflecting ongoing uncertainties in the regulatory landscape.